Close
Smartlab Europe
Inizio Ignite

AIFA awards medicines’ evaluation system contract to Accenture

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Advancing Quality 4.0 Through Centralized Drug Knowledge 

Implementation of a unified data framework serves as the catalyst for modernizing pharmaceutical production, bridging the gap between legacy processes and intelligent automation. By consolidating disparate data streams into a cohesive repository, organizations achieve unprecedented visibility into critical quality attributes and process parameters. This transformation facilitates proactive risk mitigation and ensures that Good Manufacturing Practices are maintained through high-fidelity insights rather than retrospective analysis, ultimately fostering a culture of continuous improvement and operational excellence.

Quality Risk Management and the Role of Verified Drug Information

Effective quality risk management in pharmaceutical manufacturing hinges on the availability of verified drug information to ensure GMP compliance and product safety.

Improving Pharmacovigilance with Reliable Drug Interaction and Safety Data

Robust pharmacovigilance strategies rely on the continuous integration of high-quality drug interaction and safety data to protect patient health and ensure regulatory compliance.
- Advertisement -
Smart Lab Europe

Accenture has received a contract from the Italian Medicines Agency (AIFA) to develop, build and maintain an integrated Medicine Evaluation System.

The company will provide the national authority that approves new medicines with management consulting and IT services to assist processes for administration and medical technology for the following three years.

The contract is expected to bring good stakeholder relations and build the Agency at the forefront of European medicine agencies, claims the company.Accenture Italy health and public service business lead Gianmario Pisanu said Accenture will use broad industry skills and insights from its global network to support AIFA’s mission to protect public health, provide greater access to treatment and promote research and innovation.

”We will help our client build an integrated system that reflects the needs of an organization as complex as AIFA,” Pisanu added.

Accenture provides decision support and analytic solutions for clinical care, health administration, finance and patient operations for both public and private health institutions across the globe.

 

Smart Lab Europe

Latest stories

Related stories

Advancing Quality 4.0 Through Centralized Drug Knowledge 

Implementation of a unified data framework serves as the catalyst for modernizing pharmaceutical production, bridging the gap between legacy processes and intelligent automation. By consolidating disparate data streams into a cohesive repository, organizations achieve unprecedented visibility into critical quality attributes and process parameters. This transformation facilitates proactive risk mitigation and ensures that Good Manufacturing Practices are maintained through high-fidelity insights rather than retrospective analysis, ultimately fostering a culture of continuous improvement and operational excellence.

Quality Risk Management and the Role of Verified Drug Information

Effective quality risk management in pharmaceutical manufacturing hinges on the availability of verified drug information to ensure GMP compliance and product safety.

Improving Pharmacovigilance with Reliable Drug Interaction and Safety Data

Robust pharmacovigilance strategies rely on the continuous integration of high-quality drug interaction and safety data to protect patient health and ensure regulatory compliance.

The Strategic Value of Editorially Curated Drug Databases

While raw data is abundant, the strategic value of drug information lies in editorial curation, ensuring that every interaction, dosage, and safety alert is verified by experts.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »